Top-level changes are believed to be under consideration in domestic pharma major Ranbaxy Laboratories, which may include the elevation of company president D S Brar to the post of managing director.
This would mean that Parvinder Singh, currently chairman and managing director, would relinquish the post of managing director and continue only as the chairman of the Rs 1,400-crore pharma major.
The Ranbaxy board is slated to meet on June 8. The company is also slated to hold its annual general meeting the same day at Mohali.
A company spokesperson neither confirmed nor denied the plan for top-level changes. "Dr Singh is currently abroad and Mr Brar is not available for comment on the issue," the spokesperson told Business Standard.
Company sources said Ranbaxy is also expected to announce some measures on corporate governance. The sources said this would be in line with the company's efforts to become a truly international company.
